Bone Mineral Density in HIV-Negative Men Participating in a Tenofovir Pre-Exposure Prophylaxis Randomized Clinical Trial in San Francisco
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) trials are evaluating regimens containing tenofovir-disoproxil fumarate (TDF) for HIV prevention. We determined the baseline prevalence of low bone mineral density (BMD) and the effect of TDF on BMD in men who have sex with men (MSM) in a PrEP trial in San Francisco. METHODS/FINDINGS: We evaluated 1) the prevalence of low BMD using Dual Energy X-ray Absorptiometry (DEXA) in a baseline cohort of 210 HIV-uninfected MSM who screened for a randomized clinical trial of daily TDF vs. placebo, and 2) the effects of TDF on BMD in a longitudinal cohort of 184 enrolled men. Half began study drug after a 9-month delay to evaluate changes in risk behavior associated with pill-use. At baseline, 20 participants (10%) had low BMD (Z score≤-2.0 at the L2-L4 spine, total hip, or femoral neck). Low BMD was associated with amphetamine (OR = 5.86, 95% CI 1.70-20.20) and inhalant (OR = 4.57, 95% CI 1.32-15.81) use; men taking multivitamins, calcium, or vitamin D were less likely to have low BMD at baseline (OR = 0.26, 95% CI 0.10-0.71). In the longitudinal analysis, there was a 1.1% net decrease in mean BMD in the TDF vs. the pre-treatment/placebo group at the femoral neck (95% CI 0.4-1.9%), 0.8% net decline at the total hip (95% CI 0.3-1.3%), and 0.7% at the L2-L4 spine (95% CI -0.1-1.5%). At 24 months, 13% vs. 6% of participants experienced >5% BMD loss at the femoral neck in the TDF vs. placebo groups (p = 0.13). CONCLUSIONS: Ten percent of HIV-negative MSM had low BMD at baseline. TDF use resulted in a small but statistically significant decline in BMD at the total hip and femoral neck. Larger studies with longer follow-up are needed to determine the trajectory of BMD changes and any association with clinical fractures. TRIAL REGISTRATION: ClinicalTrials.gov: NCT00131677.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant, R. M., Lama, J. R., Anderson, P. L., McMahan, V., Liu, A. Y., Vargas, L., Goicochea, P., Casapía, M., Guanira-Carranza, J. V., Ramirez-Cardich, M. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1011205 · Cited by 5,096 · cited 14×
“We determined the baseline prevalence of low bone mineral density (BMD) and the effect of TDF on BMD in men who have sex with men (MSM) in a PrEP trial in San Francisco.”
BackgroundInfluentialSelf-citationGallant, J. E. (2004) · JAMA · doi:10.1001/jama.292.2.191 · Cited by 1,341 · cited 5×
“d4T arms; bone loss in the TDF group occurred through weeks 24 and 48 in this cohort and stabilized through week 144 [16].”
BackgroundInfluentialRisk factors for HIV infection among men who have sex with men.
Koblin, B. A., Husnik, M. J., Colfax, G., Huang, Y., Madison, M., Mayer, K., Barresi, P. J., Coates, T. J., Chesney, M. A., & Buchbinder, S. (2006) · AIDS · doi:10.1097/01.aids.0000216374.61442.55 · Cited by 678
Self-citationBuchbinder, S. P., Vittinghoff, E., Heagerty, P. J., Celum, C. L., Seage, G. R., Judson, F. N., McKirnan, D., Mayer, K. H., & Koblin, B. A. (2005) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000134740.41585.f4 · Cited by 230
Self-citation
Cited by
Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana.
Thigpen, M. C., Kebaabetswe, P. M., Paxton, L. A., Smith, D. K., Rose, C. E., Segolodi, T. M., Henderson, F. L., Pathak, S. R., Soud, F. A., Chillag, K. L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110711 · Cited by 1,996
“Reasons that potential participants were ineligible other than those listed specifically in the figure included that they did not pass the comprehension test (74 volunteers), were pregnant (43), were taking long-term medication (33), expected to be relocating soon (29), were breast-feeding (13), lived outside the stud…”
BackgroundSelf-citationEffectiveness and safety of oral HIV preexposure prophylaxis for all populations
Fonner, V. A., Dalglish, S. L., Kennedy, C. E., Baggaley, R., O’Reilly, K. R., Koechlin, F. M., Rodolph, M., Hodges-Mameletzis, I., & Grant, R. M. (2016) · AIDS · doi:10.1097/qad.0000000000001145 · Cited by 993
Self-citationGünthard, H. F., Saag, M. S., Benson, C. A., del Rio, C., Eron, J. J., Gallant, J. E., Hoy, J. F., Mugavero, M. J., Sax, P. E., Thompson, M. A., et al. (2016) · JAMA · doi:10.1001/jama.2016.8900 · Cited by 656
Self-citationUS Preventive Services Task Force, Owens, D. K., Davidson, K. W., Krist, A. H., Barry, M. J., Cabana, M., Caughey, A. B., Curry, S. J., Doubeni, C. A., Epling, J. W., et al. (2019) · JAMA · doi:10.1001/jama.2019.6390 · Cited by 312
An HIV Preexposure Prophylaxis Demonstration Project and Safety Study for Young MSM
Hosek, S. G., Rudy, B., Landovitz, R., Kapogiannis, B., Siberry, G., Rutledge, B., Liu, N., Brothers, J., Mulligan, K., Zimet, G., et al. (2017) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001179 · Cited by 267
Self-citationChou, R., Evans, C., Hoverman, A., Sun, C., Dana, T., Bougatsos, C., Grusing, S., & Korthuis, P. T. (2019) · JAMA · doi:10.1001/jama.2019.2591 · Cited by 266
Spinner, C. D., Boesecke, C., Zink, A., Jessen, H., Stellbrink, H.-J., Rockstroh, J. K., & Esser, S. (2016) · Infection · doi:10.1007/s15010-015-0850-2 · Cited by 241
“Only a mild decrease in bone mineral density was observed primarily in the spine, but also less frequently in the hips [21].”
BackgroundGrohskopf, L. A., Chillag, K. L., Gvetadze, R., Liu, A. Y., Thompson, M., Mayer, K. H., Collins, B. M., Pathak, S. R., O'Hara, B., Ackers, M. L., et al. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e31828ece33 · Cited by 172
“Effects on BMD observed in this investigation have been published previously.(26) This study represents the largest safety database of US participants on oral daily PrEP to date.”
MethodSelf-citationPreexposure Prophylaxis for HIV Prevention: Where Have We Been and Where Are We Going?
Baeten, J. M., Haberer, J. E., Liu, A. Y., & Sista, N. (2013) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0b013e3182986f69 · Cited by 158
“PrEP has been associated with an average ;1% reduction in bone mineral density but not with increased fracture risk over the study period.(14,26,27) Although TDF has been associated with renal complications in HIV-infected persons, PrEP clinical trials did not find increased risk of renal complications in healthy HIV-…”
BackgroundSelf-citationGill, U. S., Zissimopoulos, A., Al-Shamma, S., Burke, K., McPhail, M. J. W., Barr, D. A., Kallis, Y. N., Marley, R. T. C., Kooner, P., Foster, G. R., et al. (2015) · Journal of Infectious Diseases · doi:10.1093/infdis/jiu471 · Cited by 93
Casado, J. L., Bañon, S., Andrés, R., Perez-Elías, M. J., Moreno, A., & Moreno, S. (2014) · Osteoporosis International · doi:10.1007/s00198-013-2506-3 · Cited by 44
Metadata
- Authors
- Liu, A. Y., Vittinghoff, E., Sellmeyer, D. E., Irvin, R., Mulligan, K., Mayer, K., Thompson, M., Grant, R., Pathak, S., O'Hara, B., Gvetadze, R., Chillag, K., Grohskopf, L., & Buchbinder, S. P.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2011-08-29
- Volume
- 6
- Issue
- 8
- Pages
- e23688
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2022226876
- Cited by
- 160
- References
- 4
- FWCI
- 17.12
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.